In conclusion, our findings establish NAT10 as an effective therapeutic target for HB, with Remodelin demonstrating promising potential to inhibit malignant progression, thereby providing a novel strategy for HB treatment. The gene discussed is NAT10; the disease is hemoglobin measurement.